Cargando…

1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes

BACKGROUND: Nasal MRSA PCR testing has been successfully implemented at many centers and limits vancomycin exposure among hospitalized patients with pneumonia. There are few studies of a Best Practice Alert (BPA) to direct nasal MRSA PCR use and vancomycin de-escalation in the absence of other stewa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenlon, Luke A, Fong, Karen, Spivak, Emily S, Imlay, Hannah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678713/
http://dx.doi.org/10.1093/ofid/ofad500.1031
_version_ 1785150428357328896
author Fenlon, Luke A
Fong, Karen
Spivak, Emily S
Imlay, Hannah
author_facet Fenlon, Luke A
Fong, Karen
Spivak, Emily S
Imlay, Hannah
author_sort Fenlon, Luke A
collection PubMed
description BACKGROUND: Nasal MRSA PCR testing has been successfully implemented at many centers and limits vancomycin exposure among hospitalized patients with pneumonia. There are few studies of a Best Practice Alert (BPA) to direct nasal MRSA PCR use and vancomycin de-escalation in the absence of other stewardship oversight. On 1/2/2020, nasal MRSA PCR and a BPA were implemented at our institution. Providers ordering vancomycin for patients with an indication of pneumonia or undifferentiated sepsis were directed to order a nasal MRSA PCR and recommended to stop vancomycin if negative (Figure 1). Our aim was to examine the impact of BPAs implementation on vancomycin duration among patients with suspected pneumonia. [Figure: see text] METHODS: A retrospective chart review was conducted among hospitalized patients without prior MRSA PCR performed during their admission who had a listed indication of pneumonia or sepsis at the time of vancomycin order. Patients were categorized into “pre” (9/17/2018 – 1/1/2020) and “post” (1/2/2020 – 3/20/2021) cohorts based on date of vancomycin order. Demographics, comorbidities, and antibiotic duration were electronically extracted. Uni- and multivariable logistic models were used to examine the proportion of patients in the pre and post cohorts whose vancomycin was stopped within 24 hours of initial order. RESULTS: A total of 2,195 patients were included, 1210 in the pre-intervention and 985 in the post-intervention cohort. After BPA implementation, 771/985 (78%) patients received a nasal MRSA PCR. Vancomycin was discontinued within 24 hours after initiation in 384/1210 (32%) patients pre-intervention and 559/985 (57%) patients post-intervention (adjusted OR 2.92 [95% CI 2.44 – 3.49], p < 0.001) (Table 1). Although “high risk” patient factors (e.g. need for mechanical ventilation) were associated with longer durations, vancomycin duration was significantly shorter in the post-implementation cohort for all “high risk” sub-groups (Figure 2). [Figure: see text] [Figure: see text] CONCLUSION: BPA directed nasal MRSA PCR testing and vancomycin de-escalation effectively shortened duration of therapy among patients with suspected pneumonia. Utilizing a BPA directed approach can improve decision efficiency and allow valuable stewardship team resources to be allocated elsewhere. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10678713
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106787132023-11-27 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes Fenlon, Luke A Fong, Karen Spivak, Emily S Imlay, Hannah Open Forum Infect Dis Abstract BACKGROUND: Nasal MRSA PCR testing has been successfully implemented at many centers and limits vancomycin exposure among hospitalized patients with pneumonia. There are few studies of a Best Practice Alert (BPA) to direct nasal MRSA PCR use and vancomycin de-escalation in the absence of other stewardship oversight. On 1/2/2020, nasal MRSA PCR and a BPA were implemented at our institution. Providers ordering vancomycin for patients with an indication of pneumonia or undifferentiated sepsis were directed to order a nasal MRSA PCR and recommended to stop vancomycin if negative (Figure 1). Our aim was to examine the impact of BPAs implementation on vancomycin duration among patients with suspected pneumonia. [Figure: see text] METHODS: A retrospective chart review was conducted among hospitalized patients without prior MRSA PCR performed during their admission who had a listed indication of pneumonia or sepsis at the time of vancomycin order. Patients were categorized into “pre” (9/17/2018 – 1/1/2020) and “post” (1/2/2020 – 3/20/2021) cohorts based on date of vancomycin order. Demographics, comorbidities, and antibiotic duration were electronically extracted. Uni- and multivariable logistic models were used to examine the proportion of patients in the pre and post cohorts whose vancomycin was stopped within 24 hours of initial order. RESULTS: A total of 2,195 patients were included, 1210 in the pre-intervention and 985 in the post-intervention cohort. After BPA implementation, 771/985 (78%) patients received a nasal MRSA PCR. Vancomycin was discontinued within 24 hours after initiation in 384/1210 (32%) patients pre-intervention and 559/985 (57%) patients post-intervention (adjusted OR 2.92 [95% CI 2.44 – 3.49], p < 0.001) (Table 1). Although “high risk” patient factors (e.g. need for mechanical ventilation) were associated with longer durations, vancomycin duration was significantly shorter in the post-implementation cohort for all “high risk” sub-groups (Figure 2). [Figure: see text] [Figure: see text] CONCLUSION: BPA directed nasal MRSA PCR testing and vancomycin de-escalation effectively shortened duration of therapy among patients with suspected pneumonia. Utilizing a BPA directed approach can improve decision efficiency and allow valuable stewardship team resources to be allocated elsewhere. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678713/ http://dx.doi.org/10.1093/ofid/ofad500.1031 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Fenlon, Luke A
Fong, Karen
Spivak, Emily S
Imlay, Hannah
1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes
title 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes
title_full 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes
title_fullStr 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes
title_full_unstemmed 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes
title_short 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes
title_sort 1191. the implementation of nasal mrsa pcr for pneumonia and association with antibiotic use and clinical outcomes
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678713/
http://dx.doi.org/10.1093/ofid/ofad500.1031
work_keys_str_mv AT fenlonlukea 1191theimplementationofnasalmrsapcrforpneumoniaandassociationwithantibioticuseandclinicaloutcomes
AT fongkaren 1191theimplementationofnasalmrsapcrforpneumoniaandassociationwithantibioticuseandclinicaloutcomes
AT spivakemilys 1191theimplementationofnasalmrsapcrforpneumoniaandassociationwithantibioticuseandclinicaloutcomes
AT imlayhannah 1191theimplementationofnasalmrsapcrforpneumoniaandassociationwithantibioticuseandclinicaloutcomes